Talis Biomedical (TLIS)
(Delayed Data from NSDQ)
$9.15 USD
+0.05 (0.55%)
Updated May 3, 2024 02:17 PM ET
After-Market: $9.32 +0.17 (1.86%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.15 USD
+0.05 (0.55%)
Updated May 3, 2024 02:17 PM ET
After-Market: $9.32 +0.17 (1.86%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -38.46% and 5.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 6.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of -16.67% and 76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?